Niagen Bioscience Acquires Core Nicotinamide Riboside (NR) Patent Portfolio

Niagen Bioscience, Inc. has acquired a comprehensive patent portfolio related to nicotinamide riboside (NR) and its salt forms from Queen’s University Belfast. This acquisition consolidates core intellectual property underlying Niagen Bioscience's NR business, making the company the sole owner of foundational patents covering NR production, composition, and commercial use. The portfolio includes patents on crystal morphologies, methods of NR synthesis, and global patent rights. This move strengthens Niagen Bioscience's leadership in NAD+ precursor intellectual property and provides enhanced financial, strategic, and operational flexibility. The company now owns over 90 issued and pending patents worldwide concerning NR and other NAD+ precursors, with more than 50 focused specifically on NR. This acquisition is expected to protect Niagen Bioscience shareholders against infringers and offers increased control over molecule development for current and future applications, including pharmaceutical uses.